Nefextinib clinical trials
Also written MAX-40279-01 and MAX-40279.
How each study uses nefextinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the nefextinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 2 |
| 2021 | 1 |
| 2022 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Maxinovel Pty., Ltd. (7)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test nefextinib.
- Sep 2027A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid LeukemiaPhase 2 · Maxinovel Pty., Ltd.
Studies
Open first, then newest update. How each study uses nefextinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid LeukemiaRecruitingPhase 2Maxinovel Pty., Ltd.NCT07743112Written as MAX-40279
- A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction CancerStatus unknownPhase 2Maxinovel Pty., Ltd.NCT05395780Written as MAX-40279
- MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML)Status unknownPhase 1Maxinovel Pty., Ltd.NCT03412292Written as MAX-40279
- MAX-40279-01 in Patients With Advanced Solid TumorsStatus unknownPhase 1Maxinovel Pty., Ltd.NCT04183764Written as MAX-40279-01
- Study of MAX-40279 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)Status unknownPhase 1Maxinovel Pty., Ltd.NCT04187495Written as MAX-40279-01
- A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal CancerStatus unknownPhase 2Maxinovel Pty., Ltd.NCT05130021Written as MAX-40279-01
- A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)Status unknownPhase 1/2Maxinovel Pty., Ltd.NCT05061147Written as MAX-40279-01
Codes
What other systems call nefextinib · ClinicalTrials.gg INT016339
- UNII (FDA) DL772G3NN7NEFEXTINIBOne source FDA
- NCI Thesaurus C174517NefextinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | DL772G3NN7 | NEFEXTINIB | One source FDA |
| NCI Thesaurus | C174517 | Nefextinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.